U.S., Liberia kick off trial of Ebola drug ZMAPP
Researchers from Liberia and the U.S. have started clinical trial tests so as to determine the effectiveness as well as the safety of ZMAPP, a drug created by Mapp Biopharmaceutical Inc.
ZMAPP, an experimental treatment, has previously been used to treat Ebola most recently on two U.S. citizens who had contracted the virus while in Liberia.
A joint effort by the National Institute of Allergy and Infectious Disease (NIAID) and the Government of Liberia will lead the trial which is set to be conducted in both countries, that is the U.S. and Liberia, among children and adults who have been infected by Ebola, the NIAID said on Friday.
According to the director of the NIAID, Dr. Anthony Fauci there is need for more research or randomized trial to be done on the drug, ZMAPP, so as to offer the scientific evidence that the drug is truly effective and safe given that there is no clear evidence that the drugged indeed offered any significant benefits despite it curing Two Americans.
The trial will see children and adults being admitted to treatment units in Liberia that cure Ebola. The research will include healthcare workers from the U.S. who got infected by the Ebola virus while assisting victims in West Africa who had the virus as well as children and adults who had acquired the virus in the U.S. through secondary transmission.
In addition to a portion of the participants receiving doses of the ZMAPP drug, all the participants who will take part in the research will be given the utmost standard of care needed for treating the Ebola virus.